Novel ADC Extends PFS in HER2-Low Breast Cancer Megan Brooks

https://www.medscape.com/viewarticle/novel-adc-extends-pfs-her2-low-breast-cancer-2026a100146i?ecd=wnl_edit_tpal_etid8832692&uac=148436CN&impID=8832692 The HER2-targeted antibody-drug conjugate (ADC) trastuzumab rezetecan more than doubled progression-free survival compared with standard chemotherapy in patients with HER2-low advanced breast cancer in the phase 3 HORIZON-Breast06 trial. Median progression-free survival was 16.4 months with the ADC vs 6.8 months with chemotherapy, representing a 73% reduction in the risk for disease progression or death.